Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.48 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.97 |
| ▸ | RAB9A | P51151 | 5/20 | 0.97 |
| ▸ | NPC1 | O15118 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | HTT | P42858 | 2/20 | 0.97 |
| ▸ | CASP6 | P55212 | 2/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.97 |
| ▸ | RELA | Q04206 | 1/20 | 0.97 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167844 | 0.98 | MAPT (1.00) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1786218 | 0.85 | MAPT (0.74) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8545403 | 0.82 | MAPT (0.67) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4329054 | 0.81 | MAPT (0.69) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13977911 | 0.79 | MAPT (0.68) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL31067261 | 0.79 | MAPT (0.68) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3113854 | 0.79 | MAPT (0.68) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15007822 | 0.79 | MAPT (0.68) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| Oxyquinoline SCHEMBL10906631 | 0.77 | MAPT (0.64) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6071988 | 0.77 | MAPT (0.60) | MAPTKDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064117-B2 | Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2006-06-20 | — | — | US | disclosed |
| US-20050038249-A1 | Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-02-17 | — | — | US | disclosed |
| EP-1363908-A4 | ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM | AUCKLAND UNISERVICES LTD (NZ) | 2004-05-06 | — | — | EP | disclosed |
| EP-1363908-A1 | ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO 3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM | Auckland Uniservices Limited (NZ) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002059122-A1 | ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM | AUCKLAND UNISERVICES LIMITED (NZ) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038249-A1 | Anti-cancer 2,3-dihydro-1H-pyrrole[3,2-f] quinoline compolexes of cobalt and chromium | CA2, HIF1AN, PPOX | ADRA2B 3737/4885ADRA2C 2183/4885CHRM3 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.